12 Results for "

Advanced gastric cancer

" in MedChemExpress (MCE) Product Catalog:
Products (12)

12 Results for "Advanced gastric cancer" in MCE Product Catalog:

  • Categories Recommended:
    More
3
3 Cited Publications
Cat. No.: HY-164992
Synonyms: MRG002; Trastuzumab MMAE
Trastuzumab vedotin (MRG002; Trastuzumab MMAE) is an antibody-drug conjugate and cytotoxin targeting HER2, with a Kd of 7.50E-11 M for human HER2. After binding to HER2, Trastuzumab vedotin undergoes internalization and lysosomal trafficking, delivering a cytotoxic payload to HER2-expressing cells and inducing tumor regression in in vivo xenograft models with HER2-expressing tumors. The anti-tumor activity of Trastuzumab vedotin is enhanced when used in combination with anti-PD-1 antibodies, and it exhibits preclinical anti-tumor activity in drug-resistant breast cancer, gastric cancer, and urothelial carcinoma PDX models. Trastuzumab vedotin has low antibody-dependent cellular cytotoxicity activity and can be used in studies related to HER2-positive breast cancer, HER2-positive gastric cancer, and unresectable locally advanced or metastatic HER2-positive urothelial carcinoma .
loading...
    loading...
Cat. No.: HY-171945
CAS No.: 2850366-99-1
Synonyms: ABBV-400; Temab-A
Telisotuzumab Adizutecan (ABBV-400) is an anti-c-Met antibody-drug conjugate (ADC). Telisotuzumab Adizutecan is composed of the humanized anti-c-Met antibody Telisotuzumab (HY-P99391) and the topoisomerase 1 inhibitor (7-MAD-MDCPT) (HY-132162). Telisotuzumab Adizutecan exhibits significant anti-tumor activity against advanced solid tumors such as colorectal cancer, gastric cancer, and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-156617A
CAS No.: 2414254-37-6
Purity:  99.75%
Synonyms: SHR169265
Research Areas:  

Cancer

(αR)-Cyclopropaneacetamide-Exatecan (SHR169265) is a DNA Topoisomerase I inhibitor with enhanced membrane permeability (with an IC50 of 1.34 μM against the human DNA Topoisomerase I). (αR)-Cyclopropaneacetamide-Exatecan exerts cytotoxic effects by inhibiting the enzymatic activity of Topoisomerase I, and this anticancer effect is independent of the expression level of HER2. (αR)-Cyclopropaneacetamide-Exatecan is an ADC Cytotoxin derived from Exatecan (HY-13631), which can be used in research related to advanced cancers such as breast cancer, gastric cancer, colorectal cancer and non-small cell lung cancer .
loading...
    loading...
Cat. No.: HY-141600
CAS No.: 1708947-48-1
Purity:  98.99%
Synonyms: BAY 1187982
Aprutumab ixadotin (BAY 1187982) is the first antibody-drug conjugate (ADC) to target FGFR2 and the first to use Auristatin-based payload. Aprutumab ixadotin contains a fully human anti-FGFR2 monoclonal antibody (Aprutumab) (HY-P99007) conjugated by lysine side chains to a non-cleavable linker and via this an innovative Auristatin W derivative. Aprutumab ixadotin can be used for the study of advanced solid tumors, such as FGFR2-positive gastric cancer and triple-negative breast cancer .
loading...
    loading...
Cat. No.: HY-P990940
CAS No.: 2883118-92-9
Synonyms: MBE-748; M-9140 Antibody; MBE-2882 Antibody

Research Areas:  

Cancer

Precemtabart is a humanized IgG1 antibody targeting CEACAM5, with selectivity for CEACAM5-positive cells. Precemtabart binds to CEACAM5 on tumor cells to deliver the topoisomerase 1 inhibitor Exatecan (HY-13631), and induces cell death by inhibiting the function of TOP1. Precemtabart inhibits the growth of CEACAM5-positive cancer cells. Precemtabart causes dose-dependent hematolymphoid and intestinal-related effects in cynomolgus monkeys. Precemtabart can be used in research related to metastatic colorectal cancer, metastatic pancreatic ductal carcinoma, advanced gastric cancer, advanced non-small cell lung cancer, and advanced pancreatic adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P991588
CAS No.: 2851060-90-5
Synonyms: AC101

Target:  

EGFR Apoptosis

Research Areas:  

Cancer

HLX-22 is a humanized monoclonal antibody targeting HER2. HLX-22 induces apoptosis in HER2-overexpressing breast and gastric cancer cells combined with Trastuzumab (HY-P9907). HLX-22 has potent antitumor activity against advanced solid tumors .
loading...
    loading...
Cat. No.: HY-13342AS
CAS No.: 2468771-43-7
Purity:  92.56%
Synonyms: YN968D1-d8 free base
Apatinib-d8 (free base) is the deuterium labeled Apatinib free base . Apatinib free base (YN968D1 free base) is an orally bioavailable tyrosine kinase inhibitor, which selectively targets VEGFR-2 (IC50=1 nM). Apatinib free base (YN968D1 free base) is an anti-angiogenic drug for the research of advanced or metastatic gastric cancer. Apatinib free base (YN968D1 free base) potently inhibits Ret, c-Kit and c-Src with IC50s of 13, 429 and 530 nM, respectively. It also inhibits cellular phosphorylation of VEGFR-2, c-kit and PDGFRβ .
loading...
    loading...
Cat. No.: HY-P991582

Research Areas:  

Cancer

BI-1607 is a humanized monoclonal antibody targeting FcγRIIB/CD32b. BI-1607 selectively blocks inhibitory FcγRIIB signaling, abrogates its inhibitory function, redirects tumor cell-bound antibodies to activating FcγRs, and its modified Fc region prevents the binding of its own Fc segment to FcγRs. BI-1607 reduces αPD-1 trogocytosis, enhances the effector functions of anti-tumor antibodies (including ADCP and ADCC, promotes intratumoral regulatory T cell (Treg) depletion, myeloid cell reprogramming, induction of interferon-γ (IFN-γ) and CXCL10, and increases the number of activated effector CD8 + T cells. BI-1607 can be used in research related to colorectal cancer, HER2-positive advanced solid tumors, HER2-positive locally advanced or metastatic breast cancer, and HER2-positive metastatic gastric cancer .
loading...
    loading...
Cat. No.: HY-119108
CAS No.: 110690-43-2
Synonyms: BOF-A2
Target:  

Drug Derivative

Research Areas:  

Cancer

Emitefur is an orally active and potent anticancer drug. Emitefur can be used for advanced gastric cancer patients .
loading...
    loading...
Cat. No.: HY-P992167

Target:  

Claudin

Research Areas:  

Cancer

AB011 is a recombinant humanized anti-CLDN18.2 IgG1 monoclonal antibody. AB011 exhibits synergistic effects with cytotoxic compounds in preclinical studies. AB011 can be used for research on advanced gastric/gastroesophageal junction adenocarcinoma and advanced pancreatic cancer .
loading...
    loading...
Cat. No.: HY-187793
CAS No.: 2412854-49-8
Synonyms: ABSK061
Target:  

FGFR

Research Areas:  

Cancer

Lavengratinib (ABSK061) is a FGFR2/FGFR3 inhibitor. Lavengratinib selectively inhibits FGFR2 and FGFR3 signaling pathways and reduces the risk of FGFR1-mediated hyperphosphatemia. Lavengratinib is suitable for research on advanced solid tumors (including cholangiocarcinoma, gastric cancer, non-small cell lung cancer, cervical cancer and urothelial cancer) .
loading...
    loading...
Cat. No.: HY-P992412

Target:  

Claudin

Research Areas:  

Cancer

MIL93 is a humanized defucosylated IgG1 monoclonal antibody targeting Claudin18.2 (CLDN18.2) with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity. MIL93 can be used for research on advanced solid tumors and gastric cancer. The recommended isotype control is human IgG1 kappa (HY-P99001) .
loading...
    loading...
  • 1